Cantor Fitzgerald analyst Olivia Brayer notes that MKT Capital announced it intention to withhold support for three Aurinia Pharmaceuticals directors at the 2023 annual meeting and says the firm is "hearing a lot of chatter around Aurinia as a potential takeout target – fueling some of the recent M&A rumors that have driven quite the inflection in shares." The firm, which adds that the stock has been "one of our top inbound interest names in our coverage list so far in 2023," has an Overweight rating and $15 price target on Aurinia shares.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AUPH:
- Aurinia Pharmaceuticals call volume above normal and directionally bullish
- Aurinia Pharmaceuticals announces method of use patent for LUPKYNIS
- Aurinia announces results from AURORA Renal Biopsy Sub-Study
- Aurinia Pharmaceuticals rumor highlighted by Betaville blog
- Aurinia Pharmaceuticals reports Q4 EPS (18c), consensus (27c)
Questions or Comments about the article? Write to editor@tipranks.com